Beam Therapeutics appoints Christi Shaw, former Kite CEO, to board of directors

Beam Therapeutics Inc.

Board expanded from 7 to 8 members; Shaw appointed as Class III director with term until 2026.
Shaw brings over 30 years biopharma experience, most recently CEO of Kite (Gilead) until March 2023.
Previously held senior roles at Lilly, Novartis, and Johnson & Johnson; currently on Avantor board.
Shaw will receive compensation per company's non-employee director policy dated March 31, 2023.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christi Shaw

member of the Board

BEAM · Beam Therapeutics Inc.

Effective: 2023-12-13
Filed: December 14, 2023, 6:59 PM ET

On December 13, 2023, the Board of Directors (the “Board”) of Beam Therapeutics Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, expanded the size of the Board from seven to eight members and elected Christi Shaw as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christi Shaw was elected as member of the Board at Beam Therapeutics Inc..

Action: elected
Role: member of the Board

Exact text from the filing

On December 13, 2023, the Board of Directors (the “Board”) of Beam Therapeutics Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, expanded the size of the Board from seven to eight members and elected Christi Shaw as a member of the Board.

View on SEC.gov

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-295457

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.